WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE)-- Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced that Gilead Sciences, Inc. has exercised its option to exclusively license KT-200, a ...
Gilead Sciences Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results